Bleeding

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020

Friday, August 7, 2020 - 2:23pm

Because of the ongoing pandemic, the conference has been rescheduled to take place from August 11-13, 2020 and will be held virtually.

Key Points: 
  • Because of the ongoing pandemic, the conference has been rescheduled to take place from August 11-13, 2020 and will be held virtually.
  • Dr. Chirag Shah is Vice President Research and Development Engineering and Quality Systems at Arch Therapeutics.
  • Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.
  • The mission of SAGES is to improve quality patient care through education, research, innovation and leadership, principally in gastrointestinal and endoscopic surgery.

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Saturday, August 1, 2020 - 4:00pm

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.
  • These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.
  • We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.
  • Our experience as leaders in hematology means we are well prepared to meet todays needs as we pursue future developments in the treatment of bleeding disorders.

Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device

Monday, July 27, 2020 - 7:00am

The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.

Key Points: 
  • The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.
  • In December 2019, Enzyre signed a collaboration with Takeda for the development of Enzypad in congenital bleeding disorders, validating this innovative approach.
  • Dirk Pollet, CEO of Enzyre commented: We are pleased to welcome Novalis Biotechnology Incubation to our investor base.
  • Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation.

Ron Simon & Associates Files Jimmy John's E. coli O103 Lawsuit After Jimmy John's Receives FDA Warning Letter

Tuesday, July 21, 2020 - 10:19pm

The lawsuit was filed against Jimmy John's on behalf of Erick Johnson, a patron who frequented a local Jimmy John's restaurant in Johnston, Iowa in December of 2019.

Key Points: 
  • The lawsuit was filed against Jimmy John's on behalf of Erick Johnson, a patron who frequented a local Jimmy John's restaurant in Johnston, Iowa in December of 2019.
  • Shortly thereafter, Erick began to experience severe nausea, abdominal cramps, and hematochezia associated with E. coli O103 (Shiga Toxin-Producing E. coli) poisoning.Johnson was hospitalized for three days at Boone County Hospital.
  • After Johnson tested positive for E. coli O103, the Greene County Health Department notified the Iowa Department of Public Health, which determined that he was sickened by the strain associated with the Jimmy John's E. coli outbreak.
  • Mr. Simon and his law firm have established a Jimmy John's E. coli Claim Center to assist victims in the outbreak.The E. coli Claim Center can be reached toll-free at 1-888-335-4901.

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

Sunday, July 12, 2020 - 1:30pm

Takeda presented a total of 13 abstracts at ISTH 2020, available on the ISTH Congress Abstracts Site .

Key Points: 
  • Takeda presented a total of 13 abstracts at ISTH 2020, available on the ISTH Congress Abstracts Site .
  • Among them, Takeda spotlighted four abstracts which support its personalized care approach for patients with bleeding disorders, especially hemophilia and VWD.
  • The data presented at ISTH 2020 demonstrate the value that innovative, personalized approaches provide to the management of hemophilia.
  • Findings presented at ISTH 2020 reaffirm Takedas commitment to support personalized care as the optimal treatment approach for patients with bleeding disorders, added Dr. med.

Majority (55 Percent) of Americans Taking Blood Thinners Indicate They Fear Suffering From Major Bleeding; 73 Percent More Cautious With Routine Activities to Avoid Risk

Tuesday, June 23, 2020 - 1:00pm

Among the 55 percent who said they fear major bleeding, nearly three-quarters (72 percent) say this concern has impacted their quality of life.

Key Points: 
  • Among the 55 percent who said they fear major bleeding, nearly three-quarters (72 percent) say this concern has impacted their quality of life.
  • Blood thinners can save lives, helping to treat and prevent dangerous blood clots, but can also pose a potentially serious side effect: Bleeding.
  • Since blood thinners slow the clotting of blood, unwanted and sometimes dangerous bleeding can occur with the use of these medications2.
  • To learn more about blood clot risks and also the signs and symptoms of blood clots, visit www.stoptheclot.org/guide

Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual Summit

Monday, June 15, 2020 - 2:00pm

The data will be presented in an oral presentation during a scientific session at the World Federation of Hemophilia Virtual Summit taking place June 14June 19, 2020.

Key Points: 
  • The data will be presented in an oral presentation during a scientific session at the World Federation of Hemophilia Virtual Summit taking place June 14June 19, 2020.
  • We look forward to sharing the results from the first study ever comparing the pharmacokinetic characteristics of Jivi versus Adynovate with the hemophilia A community.
  • Jivi can reduce the number of bleeding episodes in adults and adolescents with hemophilia A when used regularly (prophylaxis).
  • Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology.

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

Friday, June 12, 2020 - 1:20pm

KING OF PRUSSIA, Pa., June 12, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020.

Key Points: 
  • KING OF PRUSSIA, Pa., June 12, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020.
  • "CSL Behring has been on the forefront of delivering innovative treatments for people with bleeding disorders for many years and todayour commitment to address patients' unmet needs is stronger than ever," said Antti Kourula, Vice President, Hematology Therapeutic Area, CSL Behring.
  • CSL Behring is a "Collaborating Partner" of theWorld Bleeding Disorders Registry(WBDR), the world's only global registry collecting standardizedclinical data on hemophilia patients.
  • CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool

Tuesday, May 26, 2020 - 5:00pm

TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.

Key Points: 
  • TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.
  • Early diagnosis and effective surveillance can have significant positive impacts on therapeutic management, and Cellvizio is an essential tool to improve diagnostic accuracy and reduce inappropriate interventions.
  • SAGES (The Society of American Gastrointestinal and Endoscopic Surgeons) was founded in 1981 to foster, promote, support and encourage academic, clinical and research achievement in gastrointestinal endoscopic surgery.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.

GATT Technologies Announces €10.5M Series B Funding, Appointment of New CEO, and Expansion of Supervisory Board to Lead Company Through Next Development Stage

Monday, May 18, 2020 - 7:00am

Founder and current CEO Johan Bender will become responsible for R&D in his new role as CTO (Chief Technology Officer).

Key Points: 
  • Founder and current CEO Johan Bender will become responsible for R&D in his new role as CTO (Chief Technology Officer).
  • Proceeds of the investment will be used to support the next clinical trial phase and further development of applications of the Company's breakthrough hemostatic technology platform.
  • GATT Technologies' hemostats and sealants focus on controlling severe surgical bleedings as well as preventing and treating organ leakages.
  • Dr. Vlad Hogenhuis has assumed his role as board member with GATT Technologies effective May 1st, 2020.